Dynavax Technologies Corporation (NASDAQ: DVAX)
$12.8250
-0.0050 ( +0.04% ) 189.8K
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Market Data
Open
$12.8250
Previous close
$12.8300
Volume
189.8K
Market cap
$1.67B
Day range
$12.7250 - $12.8450
52 week range
$9.7400 - $15.0100
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 11, 2024 |
def | Proxies and info statements | 25 | Apr 11, 2024 |
3 | Insider transactions | 1 | Apr 05, 2024 |
8-k | 8K-related | 11 | Apr 01, 2024 |
4 | Insider transactions | 1 | Mar 19, 2024 |
8-k | 8K-related | 12 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
10-k | Annual reports | 101 | Feb 22, 2024 |
8-k | 8K-related | 14 | Feb 22, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |